{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.67","upperLimit":"20.27","value":"17.74"},{"groupId":"OG001","lowerLimit":"7.69","upperLimit":"13.54","value":"9.79"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"135"},{"groupId":"OG001","value":"129"}],"units":"Participants"}],"title":"< 1% PD-L1 Expression"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.77","upperLimit":"22.18","value":"15.80"},{"groupId":"OG001","lowerLimit":"9.49","upperLimit":"13.17","value":"10.89"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"204"},{"groupId":"OG001","value":"204"}],"units":"Participants"}],"title":">= 1% PD-L1 Expression"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.62","upperLimit":"21.22","value":"15.20"},{"groupId":"OG001","lowerLimit":"8.67","upperLimit":"12.35","value":"10.37"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"128"},{"groupId":"OG001","value":"106"}],"units":"Participants"}],"title":"with 1-49% PD-L1 Expression"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.11","upperLimit":"29.11","value":"18.91"},{"groupId":"OG001","lowerLimit":"9.36","upperLimit":"17.58","value":"12.93"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"98"}],"units":"Participants"}],"title":"with >= 50% PD-L1 Expression"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.16","upperLimit":"15.57","value":"10.84"},{"comment":"Upper Limit Not Reached","groupId":"OG001","lowerLimit":"8.64","upperLimit":"NA","value":"17.05"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"title":"Non-Quantifiable PD-L1 Expression"}],"denoms":[{"counts":[{"groupId":"OG000","value":"360"},{"groupId":"OG001","value":"358"}],"units":"Participants"}],"description":"OS was defined as the time from randomization to the date of death from any cause. OS was censored on the last date a subject was known to be alive. Survival follow-up was to be conducted every 3 months after participants's off-treatment date.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab + Ipilimumab + Chemotherapy","id":"OG000","title":"Treatment A"},{"description":"Chemotherapy only","id":"OG001","title":"Treatment B"}],"paramType":"MEDIAN","populationDescription":"All Randomized Participants, Global Population with PD-L1 measurements","reportingStatus":"POSTED","timeFrame":"From date of randomization to date of death (assessed up to October 2024, approximately 72 months)","title":"OS by PD-L1 Tumor Cell Expression","type":"SECONDARY","unitOfMeasure":"Months"}